New Patent Issued to Nanomedical Diagnostics

Nanomedical Diagnostics, a Serra Capital II portfolio company, announced a new patent issued to the company on Oct 17. The new patent is for the use of graphene biosensors with DNA probes to identify DNA sequences for precision medicine, and will enable the company’s technology to bring the benefits of lower costs, easier process, and higher throughput to the world of liquid biopsy and other DNA detection applications.

Nanomed is a life science company that has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive real-time direct detection of biomolecules. As the world’s only mass-manufacturer of graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.